Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Apr 30;6(234):234fs18.
doi: 10.1126/scitranslmed.3009118.

Using humans to make a human leishmaniasis vaccine

Shaden Kamhawi  1 , Fabiano Oliveira, Jesus G Valenzuela
Affiliations
Comment

Using humans to make a human leishmaniasis vaccine

Shaden Kamhawi et al. Sci Transl Med. .

Abstract

The cellular immune response to peptide pools from conserved Leishmania antigens in leishmaniasis-immune individuals identified epitopes for a human DNA vaccine (Das et al., this issue).

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.. LEISHDNAVAX: A TH1-inducing Leishmania DNA vaccine.
Leishmaniasis is a neglected infectious disease caused by the protozoan parasite Leishmania. Immunity and protection from leishmaniasis requires induction of a TH1 cellular immunity. This poses a challenge due to diversity of the human HLA as well as diversity of immunogenic antigens on different Leishmania species. To overcome these obstacles, Das et al. (4) used PBMCs from immune individuals residing in Tunisia and India, countries endemic for different forms of leishmaniasis, to identify sequences containing TH1-inducing epitopes conserved across Old World Leishmania species. LEISHDNAVAX was made using five MIDGE-TH1 vectors and was tested for protective effcacy against visceral leishmaniasis (VL) in mice.
See this image and copyright information in PMC

Comment on

References

    1. Desjeux P, Leishmaniasis. Nat. Rev. Microbiol 2, 692–693 (2004). - PubMed
    1. Kaye P, Scott P, Leishmaniasis: Complexity at the host-pathogen interface. Nat. Rev. Microbiol 9, 604–615 (2011). - PubMed
    1. Sundar S, Singh B, Identifying vaccine targets for anti-leishmanial vaccine development. Expert Rev. Vaccines 13, 489–505 (2014). - PMC - PubMed
    1. Das S, Freier A, Boussoffara T, Das S, Oswald D, Losch FO, Selka M, Sacerdoti-Sierra N, Schönian G, Wiesmüller K-H, Seifert K, Schroff M, Juhls C, Jaffe CL, Roy S, Das P, Louzir H, Croft SL, Modabber F, Walden P, Modular multiantigen T cell epitope–enriched DNA vaccine against human leishmaniasis. Sci. Transl. Med 6, 234ra56 (2014). - PubMed
    1. López-Fuertes L, Pérez-Jiménez E, Vila-Coro AJ, Sack F,Moreno S, Konig SA, Junghans C, Wittig B, Timón M,Esteban M, DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 21, 247–257 (2002). - PubMed

LinkOut - more resources